Coya Therapeutics, Inc. Delivers Significant Clinical, Scientific, and Financial Progress in 2025; Announces Key 2026 Catalysts

Key Highlights from FY2025 Report

• Active Clinical Development: The company has successfully launched the ALSTARS Phase 2 trial for COYA 302 in ALS, now enrolling and dosing patients at approximately 25 sites across the U.S. and Canada. Regulatory milestones include Health Canada’s Clinical Trial Application (CTA) acceptance and acknowledgment of the trial by NEALS as a NEALS-affiliated trial. The U.S. FDA has also accepted the IND application for COYA 302 in frontotemporal dementia (FTD).
• Promising Early-Stage Data: Results from an investigator-initiated study of low-dose IL-2 and CTLA4-Ig combination therapy show Treg enhancement and cognitive stability in FTD patients, providing important clinical validation of the company’s approach.
• COYA 303 Progress: Interim preclinical findings indicate potent anti-inflammatory effects and enhanced Treg function in systemic and brain inflammation models.
• Scientific Publications & Patent: Peer-reviewed results linking inflammation and oxidative stress to Parkinson’s disease were published in Frontiers in Immunology, and synergistic data on Treg protection in Journal NeuroImmune Pharmacology and Therapeutics. The company also announced issuance of a U.S. patent for a ready-to-use (RTU) liquid IL-2 formulation, covering multiple indications as monotherapy and in combination.
• Strengthened Financial Position: A \$23.0 million upsized public offering and \$11.1 million private placement (led by Dr. Reddy’s Laboratories and Greenlight Capital) have extended the company’s cash runway into the second half of 2027. As of December 31, 2025, Coya reported \$46.8 million in cash and cash equivalents.

Upcoming Potential Share Price Catalysts for 2026

• 1H 2026: Publication of peripheral immune profiling in FTD and longitudinal biomarker assessments in ALS.
• 2H 2026: Targeting full enrollment of the ALSTARS Phase 2 ALS trial, initiation of a Phase 2a FTD trial for COYA 302, additional single cell proteomics data from completed ALS and AD trials, and publication of in vivo COYA 303 data in models of inflammation.

Management Commentary

“2025 was a year of meaningful clinical and scientific progress for Coya,” said Dr. Arun Swaminathan, CEO. “We advanced COYA 302 across multiple programs and key regulatory milestones, generated encouraging translational data validating our combination-based approach, and strengthened our balance sheet to support execution through our next major clinical milestones. We enter 2026 with strong momentum and a clear path forward to advance our COYA 302 program in patients with ALS and FTD.”

Dr. Fred Grossman, President and CMO, added: “We are encouraged by the continued clinical, regulatory, and scientific momentum across our pipeline, supporting our strategy of targeting immune imbalance and neuroinflammation through regulatory T cell enhancement. We are pleased to be actively enrolling the ALSTARS trial across the US and Canada.”

Financial Results – FY2025

• Collaboration Revenues: \$7.9 million, up from \$3.6 million in 2024, primarily due to \$3.6 million increase in license revenue and \$0.7 million increase in R&D services. License revenue (\$6.7 million) was driven by milestone payments following FDA acceptance of the COYA 302 IND and first patient dosing in ALSTARS trial.
• R&D Expenses: \$16.7 million (vs. \$11.9 million in 2024), reflecting increased clinical activity for COYA 302 in ALS, internal R&D, and sponsored research, partially offset by lower preclinical expenses.
• In-Process R&D: \$2.3 million (vs. \$25,000 in 2024), due to milestone payments tied to IND acceptances and trial initiations.
• General & Administrative Expenses: \$11.4 million (vs. \$8.9 million in 2024), mainly from higher payroll/benefits, professional service fees, and increased investor/public relations costs.
• Net Loss: \$21.2 million (vs. \$14.9 million in 2024), reflecting the increased investment in R&D and operations.
• Cash and Cash Equivalents: \$46.8 million as of December 31, 2025, up from \$38.3 million at year-end 2024, primarily due to successful financing activities.
• Share Count: 20,934,456 shares outstanding as of December 31, 2025 (vs. 16,707,441 in 2024).

Balance Sheet Snapshot (December 31, 2025)

• Total Assets: \$49.95 million
• Total Liabilities: \$6.92 million
• Total Stockholders’ Equity: \$43.03 million

Potentially Price Sensitive/Shareholder-Relevant Information

• Strong cash position and extended cash runway into 2H 2027 reduces near-term financing risk and allows execution of clinical milestones.
• Meaningful clinical and regulatory advances, including successful IND acceptances, trial initiations, and promising clinical and preclinical data that support the company’s Treg-enhancing platform and pipeline.
• Multiple upcoming catalysts in 2026, including data publications, trial enrollment milestones, and the start of new clinical studies, all of which could impact share value.
• Recent patent issuance on RTU IL-2 formulation confers competitive advantage and potential intellectual property value.
• Well-respected investors (Dr. Reddy’s and Greenlight Capital) participated in the recent private placement, further validating the company’s prospects.

About Coya Therapeutics and COYA 302

Coya Therapeutics (Nasdaq: COYA), headquartered in Houston, is a clinical-stage biotech focused on regulatory T cells (Tregs) to address systemic and neuroinflammation. Its pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. COYA 302, the company’s lead program, is a combination of low-dose IL-2 and CTLA-4 Ig, intended for subcutaneous administration in ALS and FTD. It is currently in Phase 2 (ALSTARS trial) and is not yet FDA-approved.

Investor Contacts

David Snyder, CFO
[email protected]
Media: Russo Partners, David Schull ([email protected]), 858-717-2310; Rachelle Babb ([email protected]), 929-325-7559

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties. Please consult the company’s filings with the SEC, including “Risk Factors” in the Annual Report on Form 10-K, for more details. Investors should not place undue reliance on forward-looking statements and should consider their own investment objectives and risk profile before making investment decisions.

View Coya Therapeutics, Inc. Historical chart here